Private Bank & Trust Co. Purchases 676 Shares of Amgen Inc. (AMGN)
Private Bank & Trust Co. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 19.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,190 shares of the medical research company’s stock after buying an additional 676 shares during the period. Private Bank & Trust Co.’s holdings in Amgen were worth $721,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. TrimTabs Asset Management LLC raised its position in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC raised its position in shares of Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. purchased a new position in shares of Amgen during the first quarter worth approximately $106,000. Finally, Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the first quarter worth approximately $121,000. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 0.6695% during trading on Wednesday, reaching $168.9314. The company had a trading volume of 631,659 shares. Amgen Inc. has a one year low of $133.64 and a one year high of $184.21. The company has a market capitalization of $123.26 billion, a price-to-earnings ratio of 15.3868 and a beta of 1.35. The company has a 50-day moving average price of $173.92 and a 200 day moving average price of $168.25.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts expect that Amgen Inc. will post $12.58 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.70%. Amgen’s payout ratio is 41.93%.
TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/23/private-bank-trust-co-purchases-676-shares-of-amgen-inc-amgn.html.
A number of research analysts have commented on the company. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective on the stock. in a research report on Friday, July 21st. They noted that the move was a valuation call. Jefferies Group LLC restated a “hold” rating and issued a $180.00 price target on shares of Amgen in a research report on Monday, May 22nd. Leerink Swann restated a “market perform” rating and issued a $161.00 price target on shares of Amgen in a research report on Thursday, June 22nd. Credit Suisse Group set a $177.00 price target on Amgen and gave the stock a “hold” rating in a research report on Friday, July 14th. Finally, UBS AG set a $180.00 price target on Amgen and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $186.04.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.